A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, in Patients With Advanced Solid Malignancies and Lymphoma With an Expansion in Select Malignancies

Trial Profile

A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, in Patients With Advanced Solid Malignancies and Lymphoma With an Expansion in Select Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs RGX 104 (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Rgenix
  • Most Recent Events

    • 06 Jan 2017 According to a Rgenix media release, first patient has been treated in this study.
    • 01 Dec 2016 Status changed from not yet recruiting to recruiting.
    • 12 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top